Three-dimensional spheroid cultures of human prostate cancer cell lines

Prostate

Volumn 41, Issue 3, 1999, Pages 154-165

  Hedlund, Tammy E ^a   Duke, Richard C ^b   Miller, Gary J ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Prostatic cancer; Spheroids; Three dimensional tissue culture; Vitamin D

Indexed keywords

ACID PHOSPHATASE; ANDROGEN; CALCITRIOL; FAS LIGAND; PROSTATE SPECIFIC ANTIGEN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL ADHESION; CELL DIFFERENTIATION; GROWTH RATE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROSTATE CANCER; SPHEROID CELL;

ANDROGENS; APOPTOSIS; CELL ADHESION; HUMANS; MALE; PHENOTYPE; PROSTATIC NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 0032752443     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991101)41:3<154::AID-PROS2>3.0.CO;2-M     Document Type: Article

References (49)

1. von Eschenbach A, Ho R, Murphy GP, Cunningham M, Lins N. American Cancer Society guidelines for the early detection of prostate cancer: update 1997. CA Cancer J Clin 1997;47:261-264.
2. Eyre HJ. The American Cancer Society's prostate cancer position [editorial]. CA Cancer J Clin 1997;47:259-260.
3. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993;71:2031-2040.
4. Eisenberger MA, Abrams JS. Chemotherapy for prostatic carcinoma. Semin Urol 1988;6:303-310.
5. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. The LNCaP cell line - a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37:115-132.
6. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
7. Loop SM, Rozanski TA, Ostenson RC. Human primary prostate tumor cell line, ALVA-31: a new model for studying the hormonal regulation of prostate tumor cell growth. Prostate 1993; 22:93-108.
8. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol 1987;137: 1304-1306.
9. Muraki J, Addonizio JC, Choudhury MS, Fischer J, Eshghi M, Davidian MM, Shapiro LR, Wilmot PL, Nagamatsu GR, Chiao JW. Establishment of new human prostatic cancer cell line (JCA-1). Urology 1990;36:79-84.
10. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
11. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 2. Tumorigenic cell lines. Prostate 1997;30:58-64.
12. Inch WR, McCredie JA, Sutherland RM. Growth of nodular carcinomas in rodents compared with multi-cell spheroids in tissue culture. Growth 1970;34:271-282.
13. Flouriot G, Vaillant C, Salbert G, Pelissero C, Guiraud JM, Valotaire Y. Monolayer and aggregate cultures of rainbow trout hepatocytes: long-term and stable liver-specific expression in aggregates. J Cell Sci 1993;105:407-416.
14. Barcellos-Hoff MH, Aggeler J, Ram TG, Bissell MJ. Functional differentiation and alveolar morphogenesis of primary mammary cultures on reconstituted basement membrane. Development 1989;105:223-235.
15. Rak J, Mitsuhashi Y, Erdos V, Huang SN, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J Cell Biol 1995;131:1587-1598.
16. Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res 1997;57:2388-2393.
17. Lelkes PI, Galvan DL, Hayman GT, Goodwin TJ, Chatman DY, Cherian S, Garcia RM, Unsworth BR. Simulated microgravity conditions enhance differentiation of cultured PC12 cells towards the neuroendocrine phenotype. In Vitro Cell Dev Biol Anim 1998;34:316-325.
18. Ingram M, Techy GB, Saroufeem R, Yazan O, Narayan KS, Goodwin TJ, Spaulding GF. Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor. In Vitro Cell Dev Biol Anim 1997;33:459-466.
19. Zhau HE, Goodwin TJ, Chang SM, Baker TL, Chung LW. Establishment of a three-dimensional human prostate organoid coculture under microgravity-simulated conditions: evaluation of androgen-induced growth and PSA expression. In Vitro Cell Dev Biol Anim 1997;33:375-380.
20. Miller G, Stapleton G, Hedlund T, Moffatt K. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1, alpha,25-dihydroxyvitamin D3 in seven human prostate cancer cell lines. Clin Cancer Res 1995;1:997-1003.
21. Miller G, Stapleton G, Houmiel K, Ferrara J. Specific receptors for vitamin D3 in human prostatic carcinoma cells. In: Karr JP, Coffey DS, Smith RG, Tindall DJ, editors. Molecular and cellular biology of prostate cancer. New York: Plenum Press; 1991. p 253-259.
22. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha,25-dihydroxyvitamin D3. Cancer Res 1992;52:515-520.
23. Hedlund T, Moffatt K, Uskokovic M, Miller G. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. Clin Cancer Res 1997;3:1331-1338.
24. Hedlund TE, Moffatt KA, Miller GJ. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 1996;58:277-288.
25. Hedlund TE, Moffatt KA, Miller GJ. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 1996; 137:1554-1561.
26. Hedlund TE, Meech SJ, Srikanth S, Kraft AS, Miller GJ, Schaack JB, Duke RC. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ 1999;6:175-182.
27. Hedlund T, Duke R, Schleicher M, Miller G. Fas-mediated apoptosis in seven human prostate cancer cell lines: correlation with tumor stage. Prostate 1998;36:92-101.
28. Rofstad EK, Wahl A, Davies CDL, Brustad T. Growth characteristics of human melanoma multicellular spheroids in liquid-overlay culture: comparisons with the parent tumour xenografts. Cell Tissue Kinet 1986;19:205-216.
29. Hedlund TE, Miller GJ. A serum-free defined medium capable of supporting growth of four established human prostatic carcinoma cell lines. Prostate 1994;24:221-228.
30. Labarca C, Paigen K. A simple, rapid, and sensitive DNA assay procedure. Anal Biochem 1980;102:344-352.
31. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-1960.
32. Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994;14:1077-1081.
33. Berns EM, de Boer W, Mulder E. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 1986;9:247-259.
34. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha,25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun 1996;223:141-146.
35. Kachar B, Reese TS. Formation of misplaced and reflexive tight junction strands in prostate epithelial cells. J Ultrastruct Res 1983;82:90-95.
36. Merk FB, Leav I, Kwan PW, Ofner P. Effects of estrogen and androgen on the ultrastructure of secretory granules and intercellular junctions in regressed canine prostate. Anat Rec 1980; 197:111-132.
37. Brehmer B, Riemann JF, Bloodworth JM Jr, Madsen PO. Electron microscopic appearance of cells from carcinoma of the prostate in monolayer tissue culture. Urol Res 1973;1:27-31.
38. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768.
39. St. Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 1996;2:1204-1210.
40. St. Croix B, Sheehan C, Rak JW, Florenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27(KIP1). J Cell Biol 1998;142:557-571.
41. Lozano E, Cano A. Induction of mutual stabilization and retardation of tumor growth by coexpression of plakoglobin and E-cadherin in mouse skin spindle carcinoma cells. Mol Carcinog 1998;21:273-287.
42. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69: 415-429.
43. French LE, Hahne M, Viard I, Radlgruber G, Zanone R, Becker K, Muller C, Tschopp J. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133:335-343.
44. Xerri L, Devilard E, Hassoun J, Mawas C, Birg F. Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 1997;50:87-91.
45. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF. Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 1992;13:457-464.
46. Rotello RJ, Lieberman RC, Lepoff RB, Gerschenson LE. Characterization of uterine epithelium apoptotic cell death kinetics and regulation by progesterone and RU 486. Am J Pathol 1992;140: 449-456.
47. Suzuki A, Matsuzawa A, Iguchi T. Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract. Oncogene 1996;13:31-37.
48. Suzuki A, Enari M, Eguchi Y, Matsuzawa A, Nagata S, Tsujimoto Y, Iguchi T. Involvement of Fas in regression of vaginal epithelia after ovariectomy and during an estrous cycle. EMBO J 1996;15:211-215.
49. Uslu R, Borsellino N, Frost P, Garban H, Ng C, Mizutani Y, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated apoptosis. Clin Cancer Res 1997;3:963-972.